SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company
developing oral recombinant vaccines that are administered by tablet
rather than by injection, today announced that Roberto Mateo, Ph.D.,
senior scientist at Vaxart, will present preclinical results of its oral
Respiratory Syncytial Virus (RSV) vaccine in a poster presentation at
the American Society of Microbiology 2019, taking place from June 20-24,
2019 in San Francisco, California.
Details of the presentation are as follows:
|
Poster Title: |
Oral Adenovirus-Based Vaccine Induces Respiratory Mucosal |
|
|
Date & Time: |
Saturday, June 22, 2019 from 10:30 AM – 5:00 PM PST | |
|
Authors: |
Roberto Mateo, et al. | |
|
Session: |
SATURDAY- CIV Late-breakers | |
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing
oral recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart’s vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may also be useful for the treatment of chronic viral
infections and cancer. Vaxart’s vaccines are administered using a
convenient room temperature-stable tablet, rather than by
injection. Vaxart believes that tablet vaccines are easier to distribute
and administer than injectable vaccines and have the potential to
significantly increase vaccination rates. Vaxart’s development programs
include oral tablet vaccines that are designed to protect against
norovirus, seasonal influenza and respiratory syncytial virus (RSV), as
well as a therapeutic vaccine for human papillomavirus (HPV).
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, results from preclinical
and clinical trials, commercialization agreements and licenses, beliefs
and expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
“believe,” “could,” “potential,” “will” and other words and terms of
similar meaning. Examples of such statements include, but are not
limited to, statements relating to the Vaxart’s ability to develop and
commercialize its product candidates and clinical results and trial
data; the expected timing of the initiation of the Phase 1 bivalent
study and Phase 2 monovalent challenge study; and Vaxart’s expectations
with respect to the important advantages it believes its oral vaccine
platform can offer over injectable alternatives, particularly for
mucosal pathogens such as norovirus, flu and RSV. Vaxart may not
actually achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in our forward-looking statements
and you should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from the
plans, intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause actual
results or events to differ materially from the forward-looking
statements that Vaxart makes, that Vaxart’s product candidates may not
be approved by the FDA or non-U.S. regulatory authorities; that, even if
approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product
candidates may not achieve broad market acceptance; that Vaxart may
experience manufacturing issues and delays; and other risks described in
the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports
filed with the SEC. Vaxart does not assume any obligation to update any
forward-looking statements, except as required by law.
Contacts
Daniella Funaro
Stern Investor Relations
212-362-1200
vaxart@sternir.com